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GOLD stageAbstract Background: Low body mass index (BMI) in patients with chronic obstructive pul-
monary disease (COPD) was found to be more prevalent in severe stages and was associated with
poor prognosis and poor survival.
Aim: To find out the relation between BMI and GOLD stage (Global Initiative for Chronic
Obstructive Lung Disease) of COPD patients.
Methods: We conducted a cross-sectional, observational study among 154 patients of COPD,
attending the chest medicine department in our medical college during the period from January
2014 to November 2015. We classify the severity of obstruction in COPD patients according to
GOLD staging through spirometry. BMI of all the patients was measured. Correlation between
BMI and severity of obstruction (post bronchodilator forced expiratory volume in 1st second
(FEV1)% predicted) in COPD patients was determined.
Results: The mean age of all of the patients was 57.18 (SD ± 10.7) years. There were 115
(74.4%) males and 39 (25.3%) females. The COPD patients were classified by their post-
bronchodilator FEV1% predicted in four stages according to GOLD staging. Among 154 study
population, 3 (1.9%) patients were in stage 1, 54 (35.1%) in stage 2, 55 (35.7%) in stage 3, and
42 (27.3%) in stage 4. Applying the Pearson correlation test we found that BMI and post
FEV1% predicted were positively correlated (R= 0.295, P< 0.05). By applying the same test
on GOLD stage and BMI, they were found to be negatively correlated (R= 0.3, P< 0.05).
Now by applying a one-way ANOVA, we found that BMI of the patients was decreasing with sever-
ity of the disease (GOLD) and it was statistically significant (F= 4.116, P< 0.05).
Conclusion: There was positive correlation between severity of airway obstruction and BMI in
COPD patients.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death worldwide that causes more than 2.7
412 H. Hany Assal, E. Kamalmillion deaths in 2000 and it will be the third leading cause of
death worldwide by 2020 [1,2].
Malnutrition in COPD is due to increased metabolic
demands caused by basal oxygen consumption, release of
cachexia producing cytokines like tumor necrosis factor a,
interleukin 6 [3,4].
The association between low body mass index (BMI) and
poor prognosis of patients with COPD is a common clinical
observation and it varies with different stages of COPD. Nutri-
tional depletion and weight loss are features of COPD.
Patients with low BMI are at an increased risk for developing
severity of COPD [5]. Low BMI is also an independent nega-
tive determinant of survival in patients with COPD [6].
Materials and methods
This was a cross sectional, observational study. The study was
conducted in Kasr Alainy Medical School on 154 COPD
patients who attended our outpatient clinic or referred to
our Chest Department for pulmonary function assessment in
period from January 2014 to November 2015.
The subjects who were enrolled in the study were smokers
and P40 years of age with symptoms of COPD (dyspnea,
chronic cough or sputum production). Forced expiratory vol-
ume in 1st second/forced vital capacity ratio (FEV1/FVC) was
less than 0.7 on spirometry, and without any significant post-
bronchodilator FEV1 reversibility (that is, less than 12% and
200 ml).
All patients were subjected to full history taking and full
clinical examination. BMI (weight in kg/height in m2) was
measured in each patient. Pre and post-bronchodilator spirom-
etry of all the patients was done. Patients with post bron-
chodilator FEV1/FVC less than 0.7 and significant
reversibility (improvement of 12% and 200 ml of FEV1) were
excluded. Patients without significant reversibility were
selected. They were classified according to GOLD (Global Ini-
tiative for Chronic Obstructive Lung Disease) staging in stage
1 (post bronchodilator FEV1P 80%), stage 2 (post bron-
chodilator FEV1P 50% and <80%), stage 3 (post bron-
chodilator FEV1P 30 and 50%), and stage 4 (post
bronchodilator FEV1 < 30%). In our study we want to find
out the correlation between BMI and severity of obstruction
in COPD patients.
Statistical method
The data were coded and entered using the statistical package
SPSS version 15. The data were summarized using descriptiveTable 1 Age, BMI, FEV1% predicted and FEF (forced expiratory
GOLD stages.
GOLD stage Age BMI
1 Min–Max 56–71 24.49–38.
Mean (±SD) 62.67 (±7.64) 29.67 (±
2 Min–Max 40–77 19.48–52.
Mean (±SD) 56.69 (±9.57) 28.73 (±
3 Min–Max 41–80 14.69–47.
Mean (±SD) 59.13 (±11.59) 26.79 (±
4 Min–Max 42–72 15.06–48.
Mean (±SD) 54.88 (±8.19) 23.54 (±statistics: mean, standard deviation, median, minimal and
maximum values for quantitative variables and number and
percentage for qualitative values. Statistical differences
between groups were tested using chi square test for qualitative
variables, ANOVA (analysis of variance) with postHoc test for
quantitative normally distributed variables. Correlations were
done to test for linear relations between variables. P-values
less than or equal to 0.05 were considered statistically
significant.
Results
All the patients of the study population were in age range of
40–80 years. The mean age of all of the patients was 57.18
(SD± 10.7) years. Commonest age groups were 40–49 years
and 60–69 years with 45 patients in each group (29.2%). Fol-
lowed by 45 patients (29.9%) from 40 to 49 years and 22 pts
(14.3%) from 70 to 79 years. There were 115 (74.4%) males
and 39 (25.3%) females. The BMI ranged from 14.69 to
52.73 kg/m2 with a mean of 26.64 (SD± 7.58). The FEV1%
predicted ranged from 15% to 83% with a mean of 43.48%
(SD± 16.99). The FEF 25–75% predicted ranged from 5%
to 61% with a mean of 21.42% (SD ± 10.94).
The COPD patients were classified by their post bron-
chodilator FEV1% predicted in four stages according to
GOLD.
Among 154 study population, 3 (1.9%) patients were in
stage 1, 54 (35.1%) in stage 2, 55 (35.7%) in stage 3, and 42
(27.3%) in stage 4.
Table 1 shows the age, BMI, FEV1% predicted and FEF
(forced expiratory flow) 25–27% predicted of the COPD
patients in their different GOLD stages.
Applying the Pearson correlation test we found that BMI
and post FEV1% predicted were positively correlated
(R= 0.295, P< 0.05). Also BMI and FEF 25–75% predicted
were also positively correlated (R= 0.27, P< 0.05), by apply-
ing the same test on GOLD stage and BMI, they were found to
be negatively correlated (R= 0.3, P< 0.05).
By applying a one-way ANOVA, we found that BMI of the
patients was decreasing with severity of the disease (GOLD)
and it was statistically significant (F= 4.116, P< 0.05).
The post hoc Turkey test also indicated that there were sig-
nificant differences present in GOLD stages 2 and 4 of COPD
in respect to BMI. (mean BMI in stage 2 = 28.73 and in stage
4 = 23.54, P value = 0.01).
In our study sample we did not find a significant relation
between severity of obstruction and neither age nor sex
distribution.flow) 25–27% predicted of the COPD patients in their different
FEV1% predicted FEF 25–27% predicted
57 80–83 5–61
7.74) 81 (±1.73) 35.67 (±28.38)
73 50–78 15–52
7.95) 61.15 (±7.99) 31.93 (±7.31)
8 30–49 12–31
7.42) 39.72 (±5.13) 19.02 (±4.7)
89 15–29 5–17
6.42) 23.6 (±4.14) 10.05 (2.9)
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COPD is a common and progressive chronic inflammatory
condition that is responsible for a large amount of morbidity
and mortality worldwide. COPD is not only associated with
airway inflammation but also with considerable systemic
inflammation [7].
Evidence of systemic inflammation is measured
either as increased circulating cytokines, chemokines and
acute-phase proteins, or as abnormalities in circulating cells
[8].
Effects of systemic inflammation include unintentional
weight loss, skeletal muscle dysfunction, and increased risk
of cardiovascular disease, osteoporosis, gastroesophageal
reflux disorder, and depression, among others [9]. Nutritional
depletion and weight loss are common features of COPD.
The exact mechanisms are uncertain, [10] but decreased food
intake and increased energy expenditure in breathing are the
most important [11].
Several studies has demonstrated improved survival in
COPD patients with a high BMI compared to COPD with
low BMI.
Annemie et al. found that low BMI was significant indepen-
dent predictor of increased mortality in 400 COPD patients
[12].
Vestbo et al. followed 1898 COPD patients prospectively
for 7 years and found that BMI and free fat mass index were
significant predictors of mortality [13].
In the ANTADIR (Association Nationale pour le Traite-
ment a Domicile de l´Insuffisance Respiratoire Chronique) net-
work, the prognostic value of obesity in patients with COPD
was clearly demonstrated. During the 7.5 years of follow-up,
the highest survival and lowest hospitalization rates were
observed in obese COPD patients [14].
In our study we found that BMI was positively correlated
with both post-bronchodilator FEV1% predicted and FEF
25–75% (R= 0.295 and 0.27 respectively). Also BMI and
GOLD stage were found to be negatively correlated
(R= 0.3).
This was consistent with the findings of Mitra et al. who
studied the relation between BMI and severity of obstruction
in 101 male COPD patients and found that BMI of the
patients were decreasing with increasing severity of the
disease (GOLD) and it was statistically significant (P< 0.05)
[15].
Regarding the age we did not find a significant relation
between severity of obstruction and age in our study sample.
In contrast Mitra et al. found that with increase severity of
GOLD staging average age of the patient was also increasing
[15].
In 2009, Qiu et al. [16] demonstrated that there was a pos-
itive correlation present between BMI and FEV1% predicted.
Sahebjami et al. [17] also demonstrated a correlation between
BMI and pulmonary function tests and they recommended
BMI as a criterion to evaluate the nutritional status of COPD
patients.
In the Platino study, [18] a population-based epidemiologic
study conducted in five Latin American cities (2008) showed
that (GOLD) stages 3 and 4 was associated with lower BMI
in 397 male patients.Conclusion
In our study we found out that there was a positive correlation
present in between BMI and severity of obstruction in COPD
patients. With severity of the obstruction (GOLD staging)
BMI of the patient decreases and it was statistically significant.Conflict of interest
There is no conflict of interest.References
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